Equity Brief · Healthcare2026-10-27
BOI.PA·Healthcare

Boiron SA

I · AI Analysis

The brief

Boiron manufactures and sells homeopathic medicines, homeopathic specialties (branded products like Oscillococcinum for flu and Camilia for baby teething), and other healthcare items including dietary supplements, herbal remedies, cosmetics and CBD-based products [Yahoo Finance]. The company distributes through pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores and online retail [Yahoo Finance].

Boiron SA is a French manufacturer of homeopathic medicines, selling products like Oscillococcinum (for flu symptoms) and other wellness items across Europe, North America and internationally [Yahoo Finance]. The company reported trailing-twelve-month revenue of EUR 495.8M through 30 June 2026, down 2.2% in the latest reported period from a year earlier, and trades at a market cap of EUR 308.2M [Yahoo Finance]. Forward P/E of 8.3x suggests analysts expect earnings to rise, though no analyst coverage is reported for the stock [Yahoo Finance].

Profitable small-cap with solid cash generation, but revenue has contracted and institutional ownership is minimal.

The brief AI analysisConfidence 5/10

Sentinellis health

Moderate concerns

6.3/10

7.5+ strong · 4.5–7.5 moderate · under 4.5 weak

Profitability

16% of score3.3/10
Net margin+5.3%· need ≥ 12.4%, the lower third of pharma in our libraryGross margin+72.2%

Returns on capital

16% of score0.0/10
ROIC+9.6%· need > 10%Return on equity+7.0%· need > 12%

Growth & momentum

11% of score0.0/10
Revenue growth-2.2%· need ≥ 1.2%, the lower third of pharma in our libraryOperating margin trend—· no data

Balance sheet

32% of score10.0/10
Current ratio2.3xNet debt / EBITDA-0.5xInterest coverage39.6xDebt / equity0.06

Cash generation

16% of score10.0/10
Free cash flowEUR 29.7MCash vs reported profitEUR 53.2M vs EUR 32.6M

Value creation

11% of score10.0/10
ROIC vs cost of capital+4.4pp

Sentinellis calculation from the published statements — not a score reported by any data source. Each category is scored on the checks that had data; missing inputs are excluded rather than counted as failures.

Market capitalisation

EUR 308.2M

Revenue (TTM)

EUR 495.8M

Explainers

How we read these numbers

Plain-English guides · no account needed

II · Recent news

What moved

1 story · ranked by relevance

  • Company2026-10-21

    Oscillococcinum® by Boiron Helps Americans Get Ready for Flu Season - Yahoo Finance

    Yahoo Finance

Premium · Free with any account

Revenue declined 2.2% in the latest reported period from a year earlier, signaling contraction in a niche market where homeopathic medicine faces regulatory and scientific scrutiny [Yahoo Finance].

1 of 5 risks in this report

Risks

5

Opportunities

5

Red flags

2

Leadership

8

11 more findings in the full report — free with any account.

Unlock the full Boiron SA analysis

Create a free account to access the complete AI-generated report with inline citations.

  • 5 risks, 5 opportunities and 2 red flags — each with its source
  • 100+ financial metrics with charts and benchmarks
  • Full news summaries with source links
  • Executive team and compensation details
  • PDF export for offline use
Unlock all 12 findings3 free reports · No credit card

III · Related

You might also read

Same sector · Healthcare — or comparable health

Want this for your watchlist?

Read three companies free. No card.

Get 3 free reports

Produced 27 Oct 2026, 10:57 UTC

Figures come from company filings and market data. The Sentinellis health score and the wording attached to it are our interpretation of those figures, not numbers the company reported.

Not investment advice and not a recommendation to buy or sell. Sentinellis holds no positions in the companies it covers, takes no payment from issuers, and has no broker referral arrangements.

How every figure and score is calculated